11.27MMarket Cap-0.58P/E (TTM)
2.2500High1.6300Low2.47MVolume1.9800Open1.8900Pre Close4.73MTurnover37.60%Turnover RatioLossP/E (Static)6.67MShares3.760052wk High5.73P/B11.09MFloat Cap0.550052wk Low--Dividend TTM6.56MShs Float1910.0000Historical High--Div YieldTTM32.80%Amplitude0.5500Historical Low1.9160Avg Price1Lot Size
Predictive Oncology Stock Forum
Predictive Oncology Announces Agreement to be Acquired by Renovaro
Monday, 6th January at 9:10 am
- Combination creates immediate scientific synergies by harnessing complementary AI / ML platforms to improve patient outcomes across multiple cancer indications –
- Deal terms align shareholders' interest, augment business development opportunities and positioning in the capital markets -
PITTSBURGH, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NA...
1. NFA (Not Financial Advice!)
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours)
7. Remember, some stocks may get pumped WITHOUT any catal...
1. NFA
2. Do not open position without chart confirmation, indicators, momentum.
3. Scale out and secure profits. GREED will make losr and get trapped.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
7. I DO NOT give buy or sell advice
8. CH (cash on hand); AH (after hours): RTH (regular trading hours)
9. No buy pressure/momentum- No day trade.
10. Remember, some stocks may get pumped WITHOUT any catalyst this week ...
Predictive Oncology Announces Progress in Ongoing Evaluation of Strategic Alternatives
Tuesday, 3rd December at 7:00 am
PITTSBURGH, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery, today announced progress in its ongoing evaluation of strategic alternatives, which was announced on November 13, 2024.
As part of this process, the Company is considering a wide range of options with a focus on maximizi...
Predictive Oncology Reports Third Quarter 2024 Financial Results and Provides Strategic Update
Q3 2024 and Recent Highlights:
• Announced the results of an additional study that successfully demonstrated the long-term stability and viability of the more than 150,000 cryopreserved patient tumor samples stored within the Company's proprietary biobank.
◦ The samples stored in the biobank had originally been tested and cryopreserved between 2008 and 2016.
◦ The ...
No comment yet